Cargando…
HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges
Immune checkpoint inhibitors (ICIs) have become a promising immunotherapy for cancers. Human leukocyte antigen-G (HLA-G), a neoantigen, its biological functions and clinical relevance have been extensively investigated in malignancies, and early clinical trials with “anti-HLA-G strategy” are being l...
Autores principales: | Lin, Aifen, Yan, Wei-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278316/ https://www.ncbi.nlm.nih.gov/pubmed/34276691 http://dx.doi.org/10.3389/fimmu.2021.698677 |
Ejemplares similares
-
Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer
por: Chen, Qiong-Yuan, et al.
Publicado: (2021) -
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
por: Lin, Aifen, et al.
Publicado: (2018) -
Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary
por: Schwich, Esther, et al.
Publicado: (2020) -
Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC
por: Wu, Ching-Lien, et al.
Publicado: (2021) -
Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection
por: Lin, Aifen, et al.
Publicado: (2021)